Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

This study has been suspended.

Study NCT00070239 Information provided by National Cancer Institute (NCI)

First Received: October 3, 2003 Last Updated: March 13, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been suspended.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	June 2006 (Final data collection date for primary outcome measure)

Publications:

Di Vizio D, O'Connell FP, Bhattacharya N, et al.: Pharmacodynamic assessment of the cyclin-dependent kinase inhibitor flavopiridol: modulation of cdk targets in clinical samples. [Abstract] Lab Invest 85 (Suppl 1): A-1375, 297A, 2005.